Publications

• Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies.
  Kroeger, N., Pantuck, A. J., Wells, J. C., Lawrence, N., Broom, R., & Heng, D. Y. (2015). Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. European urology, 68(3), 506-515.
• Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies
  Kroeger, N., Pantuck, A. J., Wells, J. C., Lawrence, N., Broom, R., & Heng, D. Y. (2015). Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. EUROPEAN UROLOGY, 68(3), 506-515.
• Second-line therapies in metastatic urothelial carcinoma.
  Narayanan, S., Harshman, L. C., & Srinivas, S. (2015). Second-line therapies in metastatic urothelial carcinoma. Hematology/oncology clinics of North America, 29(2), 341-?.
• Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Kyriakopoulos, C. E., Chittoria, N., Choueiri, T. K., Kroeger, N., Lee, J.-L., & Rini, B. I. (2015). Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Clinical genitourinary cancer, 13(2), e79-85.
  
• International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study Ko, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., & Heng, D. Yc. (2015). International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. LANCET ONCOLOGY, 16(3), 293-300.
  
• First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium Harshman, L. C., Kroeger, N., Rha, S. Y., Donskov, F., Wood, L., & Choueiri, T. K. (2014). First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. CLINICAL GENITOURINARY CANCER, 12(5), 335-340.
  
• Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Heng, D. Yc., Wells, J. C., Rini, B. I., Beuselinck, B., Lee, J.-L., & Choueiri, T. K. (2014). Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. EUROPEAN UROLOGY, 66(4), 704-710.
  
• A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma Hussain, M., Daignault, S., Agarwal, N., Grivas, P. D., Siefker-Radtke, A. O., & Smith, D. C. (2014). A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma. CANCER, 120(17), 2684-2693.
  
• A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Alimohamed, N., Lee, J.-L., Srinivas, S., Bjarnason, G. A., Knox, J. J., & Heng, D. Yc. (2014). A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clinical genitourinary cancer, 12(4), e127-31.
  
• Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy Kroeger, N., Choueiri, T. K., Lee, J.-L., Bjarnason, G. A., Knox, J. J., & Heng, D. Yc. (2014). Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. EUROPEAN UROLOGY, 65(6), 1086-1092.
  
• Prostate Cancer, Version 2.2014 Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., & Ho, M. (2014). Prostate Cancer, Version 2.2014. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(5), 686-718.
  
• Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Conti, S. L., Thomas, I.-C., Hagedorn, J. C., Chung, B. I., Chertow, G. M., & Leppert, J. T. (2014). Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. International journal of cancer. Journal international du cancer, 134(9), 2245-2252.
  
• KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells Conti, S. L., Thomas, I.-C., Hagedorn, J. C., Chung, B. I., Chertow, G. M., & Leppert, J. T. (2014). KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. INTERNATIONAL JOURNAL OF CANCER, 134(9), 2245-2252.
  
• First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC Ko, J. J., Choueiri, T. K., Rini, B. I., Lee, J.-L., Kroeger, N., & Heng, D. Yc. (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. BRITISH JOURNAL OF CANCER, 110(8), 1917-1922.
  
• The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium Schutz, F. Ab., Xie, W., Donskov, F., Sircar, M., McDermott, D. F., & Choueiri, T. K. (2014). The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. EUROPEAN UROLOGY, 65(4), 723-730.
  
• Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Srinivas, S., & Saigal, C. S. (2014). Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma. UROLOGY, 83(4), 774-779.
  
• Reply. Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Brooks, J. D., & Saigal, C. S. (2014). Reply. Urology, 83(4), 779-780.
  
• Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy McKay, R. R., Kroeger, N., Xie, W., Lee, J.-L., Knox, J. J., & Choueiri, T. K. (2014). Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. EUROPEAN UROLOGY, 65(3), 577-584.
  
• Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials Heng, D. Yc., Choueiri, T. K., Rini, B. I., Lee, J., Yuasa, T., & Wood, L. A. (2014). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. ANNALS OF ONCOLOGY, 25(1), 149-154.
  
• Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., & Ho, M. (2013). Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(12), 1471-1479.
  
• Prostate cancer, version 1.2014. Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., & Ho, M. (2013). Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network , 11(12), 1471-1479.
  
• Utilization of renal mass biopsy in patients with renal cell carcinoma Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Srinivas, S., & Saigal, C. S. (2013). Utilization of renal mass biopsy in patients with renal cell carcinoma. BJU INTERNATIONAL, 112, 14-14.
  
• Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era Conti, S. L., Thomas, I.-C., Hagedorn, J. C., Chung, B. I., Chertow, G. M., & Leppert, J. T. (2013). Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. BJU INTERNATIONAL, 112, 14-16.
  
• Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma Fishman, M. N., Srinivas, S., Hauke, R. J., Amato, R. J., Esteves, B., & Kabbinavar, F. F. (2013). Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma. EUROPEAN JOURNAL OF CANCER, 49(13), 2841-2850.
  
• Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial Harrop, R., Chu, F., Gabrail, N., Srinivas, S., Blount, D., & Ferrari, A. (2013). Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. CANCER IMMUNOLOGY IMMUNOTHERAPY, 62(9), 1511-1520.
  
• Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria Kroeger, N., Xie, W., Lee, J.-L., Bjarnason, G. A., Knox, J. J., & Heng, D. Yc. (2013). Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. CANCER, 119(16), 2999-3006.
  
• A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer Dreicer, R., Garcia, J., Rini, B., Vogelzang, N., Srinivas, S., & Raghavan, D. (2013). A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. INVESTIGATIONAL NEW DRUGS, 31(4), 1044-1050.
  
• NCCN Task Force Report: Bone Health in Cancer Care Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., & Van Poznak, C. H. (2013). NCCN Task Force Report: Bone Health in Cancer Care. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11, S1-S50.
  
• NCCN Task Force Report: Bone Health In Cancer Care. Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., & Van Poznak, C. H. (2013). NCCN Task Force Report: Bone Health In Cancer Care. Journal of the National Comprehensive Cancer Network , 11, S1-50.
  
• A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma Harshman, L. C., Barbeau, S., McMillian, A., & Srinivas, S. (2013). A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma. CLINICAL GENITOURINARY CANCER, 11(2), 100-106.
  
• Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC) Harshman, L. C., Yu, R. J., Allen, G. I., Srinivas, S., Gill, H. S., & Chung, B. I. (2013). Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 31(3), 379-385.
  
• Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., & Hussain, M. (2013). Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. JOURNAL OF CLINICAL ONCOLOGY, 31(4), 412-419.
  
• The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013). The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC-HEART FAILURE, 1(1), 72-78.
  
• Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., & Srinivasan, R. (2013). Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 31(2), 181-186.
  
• Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone Ryan, C. J., Rosenthal, M., Ng, S., Alumkal, J., Picus, J., & Gerritsen, W. R. (2013). Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. CLINICAL CANCER RESEARCH, 19(1), 215-224.
  
• mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer Cann, G. M., Gulzar, Z. G., Cooper, S., Li, R., Luo, S., & Talasaz, Aa. H. (2012). mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer. PLOS ONE, 7(11).
  
• Variations in Normal Serum Alpha-Fetoprotein (AFP) Levels in Patients with Testicular Cancer on Surveillance Patel, P., Balise, R., & Srinivas, S. (2012). Variations in Normal Serum Alpha-Fetoprotein (AFP) Levels in Patients with Testicular Cancer on Surveillance. ONKOLOGIE, 35(10), 588-591.
  
• Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study Harshman, L. C., Xie, W., Bjarnason, G. A., Knox, J. J., MacKenzie, M., & Choueiri, T. K. (2012). Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. LANCET ONCOLOGY, 13(9), 927-935.
  
• Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines Mohler, J. L., Armstrong, A. J., Bahnson, R. R., Boston, B., Busby, J. E., & Shead, D. A. (2012). Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(9), 1081-1087.
  
• Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies. Hall, P. S., Witteles, R., Srinivas, S., & Harshman, L. C. (2012). Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
  
• Evaluation of ERCC1 and RRM1 as prognostic biomarkers in urothelial cancer (UC) treated with adjuvant platinum and gemcitabine chemotherapy. Harshman, L. C., Bepler, G., Quinn, D. I., McKenney, J., Hawes, D., & Dorff, T. B. (2012). Evaluation of ERCC1 and RRM1 as prognostic biomarkers in urothelial cancer (UC) treated with adjuvant platinum and gemcitabine chemotherapy. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
  
• Phase 1 trial of tivozanib (AV-951) combined with temsirolimus in patients with renal cell carcinoma Srinivas, S., Kabbinavar, F. F., Hauke, R. J., Esteves, B., Cotreau, M. M., & Fishman, M. N. (2012). Phase 1 trial of tivozanib (AV-951) combined with temsirolimus in patients with renal cell carcinoma. BJU INTERNATIONAL, 109, 10-11.
  
• Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease Dreicer, R., Garcia, J., Hussain, M., Rini, B., Vogelzang, N., & Raghavan, D. (2011). Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. INVESTIGATIONAL NEW DRUGS, 29(6), 1441-1448.
  
• Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer Oh, W. K., Galsky, M. D., Stadler, W. M., Srinivas, S., Chu, F., & Ross, R. W. (2011). Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer. UROLOGY, 78(3), 626-630.
  
• Toxicities of targeted agents in advanced renal cell carcinoma. Patel, P., & Srinivas, S. (2011). Toxicities of targeted agents in advanced renal cell carcinoma. Current clinical pharmacology, 6(3), 181-188.
  
• Pyoderma Gangrenosum With the Use of Sunitinib Nadauld, L. D., Miller, M. B., & Srinivas, S. (2011). Pyoderma Gangrenosum With the Use of Sunitinib. JOURNAL OF CLINICAL ONCOLOGY, 29(10), E266-E267.
  
• NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy Hudes, G. R., Carducci, M. A., Choueiri, T. K., Esper, P., Jonasch, E., & Srinivas, S. (2011). NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9, S1-S29.
  
• NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, & Srinivas S. (2011). NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. J Natl Compr Canc Network, 9.
  
• Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients Harshman, L. C., Bepler, G., Zheng, Z., Higgins, J. P., Allen, G. I., & Srinivas, S. (2010). Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU INTERNATIONAL, 106(11), 1805-1811.
  
• Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC Pili, R., Rosenthal, M. A., Mainwaring, P. N., van Hazel, G., Srinivas, S., & Clingan, P. (2010). Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC. CLINICAL CANCER RESEARCH, 16(10), 2906-2914.
  
• Prostate Cancer Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., & Walsh, P. C. (2010). Prostate Cancer. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(2), 162-200.
  
• The bevacizumab experience in advanced renal cell carcinoma Harshman, L. C., & Srinivas, S. (2010). The bevacizumab experience in advanced renal cell carcinoma. ONCOTARGETS AND THERAPY, 3, 179-189.
  
• Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer Bazan JG, King CR, Brooks JD, & Srinivas S. (2010). Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer. Open Prostate Cancer Journal, 3.
  
• RRM1 expression in muscle invasive, locally advanced urothelial cancer is associated with survival in younger patients Harshman, L., Bepler, G., Zheng, Z., Higgins, J., Allen, G., & Srinivas, S. (2009). RRM1 expression in muscle invasive, locally advanced urothelial cancer is associated with survival in younger patients. EJC SUPPLEMENTS, 7(4), 19-19.
  
• A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer Srinivas, S., & Feldman, D. (2009). A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer. ANTICANCER RESEARCH, 29(9), 3605-3610.
  
• Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Escudier, B., Roigas, J., Gillessen, S., Harmenberg, U., Srinivas, S., & Vogelzang, N. J. (2009). Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 27(25), 4068-4075.
  
• Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib Harshman, L. C., Srinivas, S., Kamaya, A., & Chung, B. I. (2009). Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. NATURE REVIEWS UROLOGY, 6(6), 338-343.
  
• NCCN Task Force Report: Bone Health in Cancer Care Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., & Van Poznak, C. H. (2009). NCCN Task Force Report: Bone Health in Cancer Care. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 7, S1-S32.
  
• Correlation of RRM1 expression in muscle invasive locally advanced urothelial cancer with age Harshman, L. C., Bepler, G., Zheng, Z., Higgins, J. P., ALLEN, G. I., & Srinivas, S. (2009). Correlation of RRM1 expression in muscle invasive locally advanced urothelial cancer with age. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Krishnan, A. V., Srinivas, S., & Feldman, D. (2009). Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermato-endocrinology, 1(1), 7-11.
  
• High dose chemotherapy followed by stem cell rescue for high risk germ cell tumors: the Stanford experience. Agarwal R, Dvorak CC, Stockerl- Goldstein KE, Johnson L, & Srinivas S. (2009). High dose chemotherapy followed by stem cell rescue for high risk germ cell tumors: the Stanford experience. Bone Marrow Transplant, 43(7).
  
• Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer Krishnan AV, Srinivas S, & Feldman D. (2009). Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer. Dermato Endocrinolgy, 1.
  
• A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma Srinivas, S., & Harshman, L. C. (2009). A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma. CHEMOTHERAPY, 55(5), 321-326.
  
• Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma Harshman, L. C., Kuo, C. J., Wong, B. Y., Vogelzang, N. J., & Srinivas, S. (2009). Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma. CANCER INVESTIGATION, 27(8), 851-856.
  
• Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma Harshman, L. C., Kuo, C. J., Wong, B. Y., Vogelzang, N. J., & Srinivas, S. (2008). Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma. BLOOD, 112(11), 1185-1185.
  
• The Combination of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma - Is Not the Answer Harshman, L. C., Li, M., & Srinivas, S. (2008). The Combination of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma - Is Not the Answer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 31(5), 417-423.
  
• Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613-1618.
  
• Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma Jonasch, E., Stadler, W. M., Bukowski, R. M., Hayes, T. G., Varadhachary, A., & Srinivas, S. (2008). Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. CANCER, 113(1), 72-77.
  
• Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC) Harshman, L. C., Kuo, C. J., & Srinivas, S. (2008). Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma (mRCC). JOURNAL OF CLINICAL ONCOLOGY, 26(15).
  
• Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer Harshman, L., & Srinivas, S. (2008). Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. ONKOLOGIE, 31(8-9), 432-433.
  
• Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma Harshman, L. C., & Srinivas, S. (2007). Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. EXPERT REVIEW OF ANTICANCER THERAPY, 7(12), 1749-1761.
  
• A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) Ross, R. W., Srinivasan, R., Vaishampayan, U., Bukowski, R., Rosenberg, J., & Keer, H. N. (2007). A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). MOLECULAR CANCER THERAPEUTICS, 6(12), 3511S-3511S.
  
• Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer Bukowski, R. M., Kabbinavar, F. F., Figlin, R. A., Flaherty, K., Srinivas, S., & McDermott, D. (2007). Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(29), 4536-4541.
  
• Acute pancreatitis associated with sorafenib Li, M., & Srinivas, S. (2007). Acute pancreatitis associated with sorafenib. SOUTHERN MEDICAL JOURNAL, 100(9), 909-911.
  
• Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer Feldman, D., Krishnan, A., Moreno, J., Swami, S., Peehl, D. M., & Srinivas, S. (2007). Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. NUTRITION REVIEWS, 65(8), S113-S115.
  
• Prostate cancer. Clinical practice guidelines in oncology. Mohler, J., Babaian, R. J., Bahnson, R. R., Boston, B., D'Amico, A., & Walsh, P. C. (2007). Prostate cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 5(7), 650-683.
  
• Bone related events in high risk prostate cancer Srinivas, S., & Colocci, N. (2006). Bone related events in high risk prostate cancer. JOURNAL OF UROLOGY, 176(6), S50-S54.
  
• Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade King, C. R., McNeal, J. E., Gill, H., Brooks, J. D., Srinivas, S., & Presti, J. C. (2006). Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. UROLOGY, 67(6), 1229-1234.
  
• Nonplatinum therapy in advanced bladder cancer Srinivas, S., & Colocci, N. (2006). Nonplatinum therapy in advanced bladder cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 6(6), 887-894.
  
• Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer Srinivas, S., Krishnan, A. V., Colocci, N., & Feldman, D. (2006). Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. UROLOGY, 67(5), 1001-1006.
  
• Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy Liu, I. J., Lai, Y.-H., Espiritu, J. I., Segall, G. M., Srinivas, S., & Terris, M. K. (2006). Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. UROLOGIA INTERNATIONALIS, 77(1), 69-75.
  
• Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. Badger, J., Kang, S., Uzieblo, A., & Srinivas, S. (2005). Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. Journal of clinical oncology , 23(28), 7224-7225.
  
• A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma Srinivas, S., & Guardino, A. E. (2005). A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU INTERNATIONAL, 96(4), 536-539.
  
• A nonplatinum combination in metastatic transitional cell carcinoma Srinivas, S., & Guardino, A. E. (2005). A nonplatinum combination in metastatic transitional cell carcinoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 28(2), 114-118.
  
• Node Positive Bladder Cancer Srinivas S, & Freiha F. (2005). Node Positive Bladder Cancer. Arab J Urology, 3.
  
• Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis Morgan, K., Srinivas, S., & Freiha, F. S. (2004). Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis. UROLOGY, 64(4).
  
• Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies. Srinivas, S., & Guardino, A. E. (2004). Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 425S-425S.
  
• Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily Murphy, J. C., Srinivas, S., & Terris, M. K. (2004). Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily. JOURNAL OF ANDROLOGY, 25(4), 630-634.
  
• Positron emission tomography in the initial staging of esophageal cancer Wren, S. M., Stijns, P., & Srinivas, S. (2002). Positron emission tomography in the initial staging of esophageal cancer. ARCHIVES OF SURGERY, 137(9), 1001-1006.
  
• Utility of bone scan post primary therapy in prostate cancer Srinivas S. (2002). Utility of bone scan post primary therapy in prostate cancer. UroOncology.
  
• Management choices in stage I non-seminomatous Germ Cell Tumor Srinivas S, & Terris MK. (2001). Management choices in stage I non-seminomatous Germ Cell Tumor. UroOncology.
  
• Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer Kiratli, B. J., Srinivas, S., Perkash, I., & Terris, M. K. (2001). Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. UROLOGY, 57(1), 127-132.
  
• High-dose chemotherapy in poor-risk germ-cell tumors Srinivas, S. (2000). High-dose chemotherapy in poor-risk germ-cell tumors. ONCOLOGY-NEW YORK, 14(10), 1419-1423.
  
• Spontaneous pneumothorax in malignancy: A case report and review of the literature Srinivas, S., & Varadhachary, G. (2000). Spontaneous pneumothorax in malignancy: A case report and review of the literature. ANNALS OF ONCOLOGY, 11(7), 887-889.
  
• Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer. Durski, J. M., Srinivas, S., & Segall, G. (2000). Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer. Clinical positron imaging : official journal of the Institute for Clinical P.E.T, 3(3), 97-105.
  
• Actinomycin D revisited in testicular cancer. A case report Srinivas, S., & Freiha, F. S. (1999). Actinomycin D revisited in testicular cancer. A case report. TUMORI, 85(1), 78-79.
  
• Tool support for authoring eligibility criteria for cancer trials Rubin, D. L., Gennari, J. H., Srinivas, S., Yuen, A., Kaizer, H., & Silva, J. S. (1999). Tool support for authoring eligibility criteria for cancer trials. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 369-373.
  
• Methotrexate tolerance in patients with ileal conduits and continent diversions Srinivas, S., Mahalati, K., & Freiha, F. S. (1998). Methotrexate tolerance in patients with ileal conduits and continent diversions. CANCER, 82(6), 1134-1136.
  
• Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer Small, E. J., Srinivas, S., Egan, B., McMillan, A., & Rearden, T. P. (1996). Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 14(5), 1617-1625.
  
• THE ANTIANDROGEN WITHDRAWAL SYNDROME - EXPERIENCE IN A LARGE COHORT OF UNSELECTED PATIENTS WITH ADVANCED PROSTRATE CANCER Small, E. J., & Srinivas, S. (1995). THE ANTIANDROGEN WITHDRAWAL SYNDROME - EXPERIENCE IN A LARGE COHORT OF UNSELECTED PATIENTS WITH ADVANCED PROSTRATE CANCER. CANCER, 76(8), 1428-1434.
  
• THE WEIGHT-BASED HEPARIN DOSING NOMOGRAM COMPARED WITH A STANDARD CARE NOMOGRAM - A RANDOMIZED CONTROLLED TRIAL Raschke, R. A., Reilly, B. M., Guidry, J. R., Fontana, J. R., & Srinivas, S. (1993). THE WEIGHT-BASED HEPARIN DOSING NOMOGRAM COMPARED WITH A STANDARD CARE NOMOGRAM - A RANDOMIZED CONTROLLED TRIAL. ANNALS OF INTERNAL MEDICINE, 119(9), 874-881.
  
• INTRAVENOUS HEPARIN DOSING - PATTERNS AND VARIATIONS IN INTERNISTS PRACTICES Reilly, B. M., Raschke, R., Srinivas, S., & Nieman, T. (1993). INTRAVENOUS HEPARIN DOSING - PATTERNS AND VARIATIONS IN INTERNISTS PRACTICES. JOURNAL OF GENERAL INTERNAL MEDICINE, 8(10), 536-542.